Sirolimus: its discovery, biological properties, and mechanism of action.
Level 5 - mechanism / opinion, no new human data
Narrative review of drug discovery, preclinical data, and molecular mechanism without systematic synthesis.
PubMed 12742462 · doi:10.1016/s0041-1345(03)00211-2
What was done
This narrative review outlines the discovery, biological properties, preclinical antitumor profile, immunosuppressive activities, and molecular mechanism of action of sirolimus (rapamycin).
What was found
No quantitative data or statistical metrics are reported in the abstract. The narrative describes sirolimus as a natural product isolated from *Streptomyces hygroscopicus* with antifungal activity, broad antitumor effects in murine tumor models (B16 melanocarcinoma, Colon 26, EM ependymoblastoma, and mammary/colon 38 tumors), and potent inhibition of antigen-induced T-cell, B-cell, and antibody proliferation. Mechanistically, sirolimus complexes with intracellular FKBP12 to inhibit the cell-cycle kinase TOR, arresting cell-cycle progression at the G1/S transition.
Why it matters
It synthesizes the mechanistic basis and preclinical rationale for using sirolimus as an immunosuppressive agent for renal graft rejection prophylaxis.
Limits
The abstract provides no original human clinical data, no quantitative effect estimates, and no systematic review search methodology.
Cited by
- supports Sirolimus (rapamycin) is a naturally occurring compound discovered in a soil sample from Easter Island (Rapa Nui).